Associations - JAK2 (Janus kinase 2)

CRLF2 rearrangement + JAK2 fusion	Childhood B Acute Lymphoblastic Leukemia	CRLF2 rearrangement + JAK2 fusion	Childhood B Acute Lymphoblastic Leukemia	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2
JAK2 fusion	Childhood B Acute Lymphoblastic Leukemia	JAK2 fusion	Childhood B Acute Lymphoblastic Leukemia	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2
JAK2 mutation	Acute Myelogenous Leukemia	JAK2 mutation	Acute Myelogenous Leukemia	ruxolitinib Sensitive: C2 – Inclusion Criteria ruxolitinib Sensitive : C2	ruxolitinib Sensitive: C2 – Inclusion Criteria ruxolitinib Sensitive : C2
JAK2 mutation	Leukemia	JAK2 mutation	Leukemia	ruxolitinib Sensitive: C2 – Inclusion Criteria ruxolitinib Sensitive : C2	ruxolitinib Sensitive: C2 – Inclusion Criteria ruxolitinib Sensitive : C2
JAK2 mutation	Acute Myelogenous Leukemia	JAK2 mutation	Acute Myelogenous Leukemia	LY3009120 Sensitive: C3 – Early Trials LY3009120 Sensitive : C3	LY3009120 Sensitive: C3 – Early Trials LY3009120 Sensitive : C3
JAK2 deletion	Non Small Cell Lung Cancer	JAK2 deletion	Non Small Cell Lung Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
JAK2 underexpression	Cutaneous Melanoma	JAK2 underexpression	Cutaneous Melanoma	TL-1-85 Sensitive: C3 – Early Trials TL-1-85 Sensitive : C3	TL-1-85 Sensitive: C3 – Early Trials TL-1-85 Sensitive : C3
JAK2 underexpression	Cutaneous Melanoma	JAK2 underexpression	Cutaneous Melanoma	QL-VIII-58 Sensitive: C3 – Early Trials QL-VIII-58 Sensitive : C3	QL-VIII-58 Sensitive: C3 – Early Trials QL-VIII-58 Sensitive : C3
JAK2 amplification	Non Small Cell Lung Cancer	JAK2 amplification	Non Small Cell Lung Cancer	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3
JAK2 underexpression	Cutaneous Melanoma	JAK2 underexpression	Cutaneous Melanoma	ruxolitinib Resistant: C3 – Early Trials ruxolitinib Resistant : C3	ruxolitinib Resistant: C3 – Early Trials ruxolitinib Resistant : C3
JAK2 underexpression	Cutaneous Melanoma	JAK2 underexpression	Cutaneous Melanoma	fedratinib Resistant: C3 – Early Trials fedratinib Resistant : C3	fedratinib Resistant: C3 – Early Trials fedratinib Resistant : C3
JAK2 underexpression	Cutaneous Melanoma	JAK2 underexpression	Cutaneous Melanoma	sunitinib Resistant: C3 – Early Trials sunitinib Resistant : C3	sunitinib Resistant: C3 – Early Trials sunitinib Resistant : C3

JAK2 (Janus kinase 2)

Associations(48)

Associations
(48)